Generic Exclusivity Does Not Apply After Challenged Patent Expires - FDA
Executive Summary
The 180-day exclusivity for first generics cannot extend beyond the expiration of the patent challenged in the ANDA's paragraph IV certification, FDA said in granting exclusivity to American Pharmaceutical Partners for generic cisplatin even though it was not the first company to submit an ANDA for the drug.
You may also be interested in...
“Shared” Generic Exclusivity In Multi-Patent Cases Speeds Launch – FDA
Providing shared exclusivity to generic applicants ensures faster access to market for generics, FDA said in explaining its shift from a "patent by patent" approach to 180-day exclusivity
“Shared” Generic Exclusivity In Multi-Patent Cases Speeds Launch – FDA
Providing shared exclusivity to generic applicants ensures faster access to market for generics, FDA said in explaining its shift from a "patent by patent" approach to 180-day exclusivity
Generic Exclusivity "Incentive" Needs Review, FDA's Dickinson Says
The necessity of 180-day generic exclusivity should be reviewed, FDA Associate Counsel for Drugs Elizabeth Dickinson told the Food & Drug Law Institute conference on the Waxman/Hatch Act Dec. 11 in Washington, D.C.